<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News</title>
	<atom:link href="https://www.worldpharmatoday.com/news/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Thu, 17 Sep 2026 07:21:49 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.1</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>News</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Top 5 AI Molecule Design Software Platforms in 2026</title>
		<link>https://www.worldpharmatoday.com/news/top-5-ai-molecule-design-software-platforms-in-2026/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 17 Sep 2026 07:21:49 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/top-5-ai-molecule-design-software-platforms-in-2026/</guid>

					<description><![CDATA[<p>Generating a molecule is easy for a modern AI model. Generating one that a discovery team should actually make is considerably harder. A useful candidate has to satisfy several constraints at once. It may need stronger binding without losing selectivity, improved stability without damaging activity, sufficient novelty without becoming synthetically unrealistic, or better affinity without [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/top-5-ai-molecule-design-software-platforms-in-2026/">Top 5 AI Molecule Design Software Platforms in 2026</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>FDA Opens Door to Innovative Approaches for Psychedelic Drug Development Amid Mental Health Crisis</title>
		<link>https://www.worldpharmatoday.com/news/fda-opens-door-to-innovative-approaches-for-psychedelic-drug-development-amid-mental-health-crisis/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 14:22:47 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/fda-opens-door-to-innovative-approaches-for-psychedelic-drug-development-amid-mental-health-crisis/</guid>

					<description><![CDATA[<p>Senior officials at the US Food and Drug Administration have signaled that the agency is open to novel and innovative approaches in the clinical development of psychedelic drugs, citing the worsening mental health crisis across the United States. The agency&#8217;s evolving regulatory stance was formally outlined in an article published in the New England Journal [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/fda-opens-door-to-innovative-approaches-for-psychedelic-drug-development-amid-mental-health-crisis/">FDA Opens Door to Innovative Approaches for Psychedelic Drug Development Amid Mental Health Crisis</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>ABEC Opens New Biopharmaceutical Manufacturing Facility in Wilson, North Carolina</title>
		<link>https://www.worldpharmatoday.com/news/abec-opens-new-biopharmaceutical-manufacturing-facility-in-wilson-north-carolina/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 14:04:55 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/abec-opens-new-biopharmaceutical-manufacturing-facility-in-wilson-north-carolina/</guid>

					<description><![CDATA[<p>ABEC is set to open a new manufacturing facility in Wilson, North Carolina, further strengthening its network of biopharmaceutical process equipment and consumables production. A ribbon-cutting ceremony to mark the occasion is scheduled for 24 September, with company leadership, employees, partners, and community leaders expected to attend. A New Hub for Bioprocess Equipment and Consumables [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/abec-opens-new-biopharmaceutical-manufacturing-facility-in-wilson-north-carolina/">ABEC Opens New Biopharmaceutical Manufacturing Facility in Wilson, North Carolina</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>UK Review Recommends &#8216;L Plates&#8217; for New Healthcare AIs</title>
		<link>https://www.worldpharmatoday.com/news/uk-review-recommends-l-plates-for-new-healthcare-ais/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 13:56:15 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/uk-review-recommends-l-plates-for-new-healthcare-ais/</guid>

					<description><![CDATA[<p>The National Commission into the Regulation of AI in Healthcare has delivered its long-awaited report, setting out a framework for deploying artificial intelligence tools within the National Health Service in a manner described as &#8220;safe, fast, and trusted.&#8221; Commissioned by the Medicines and Healthcare Products Regulatory Agency (MHRA), the report concludes that the existing regulatory [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/uk-review-recommends-l-plates-for-new-healthcare-ais/">UK Review Recommends ‘L Plates’ for New Healthcare AIs</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Hengrui Wins World-First Approval for Hetrombopag in Chemotherapy-Induced Thrombocytopenia</title>
		<link>https://www.worldpharmatoday.com/news/hengrui-wins-world-first-approval-for-hetrombopag-in-chemotherapy-induced-thrombocytopenia/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 11 Sep 2026 13:49:46 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/hengrui-wins-world-first-approval-for-hetrombopag-in-chemotherapy-induced-thrombocytopenia/</guid>

					<description><![CDATA[<p>Jiangsu Hengrui Pharma has secured a landmark regulatory clearance in China for its oral thrombopoietin (TPO) receptor agonist hetrombopag, making it the first oral TPO agonist anywhere in the world to receive approval for chemotherapy-induced thrombocytopenia (CIT). The approval was granted by China&#8217;s National Medical Products Administration (NMPA) and positions Hengrui in a category of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/hengrui-wins-world-first-approval-for-hetrombopag-in-chemotherapy-induced-thrombocytopenia/">Hengrui Wins World-First Approval for Hetrombopag in Chemotherapy-Induced Thrombocytopenia</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Why FDA 510(k) Clearance and EU CE MDR Certification Should Anchor Your Hearing Aid Sourcing Strategy</title>
		<link>https://www.worldpharmatoday.com/news/why-fda-510k-clearance-and-eu-ce-mdr-certification-should-anchor-your-hearing-aid-sourcing-strategy/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 10 Sep 2026 10:53:36 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/why-fda-510k-clearance-and-eu-ce-mdr-certification-should-anchor-your-hearing-aid-sourcing-strategy/</guid>

					<description><![CDATA[<p>Introduction For e-commerce platforms, hospital procurement directors, healthcare supply chain managers, and medical device importers, hearing aid sourcing has moved far beyond simple price-per-unit comparisons. The international medical device landscape now demands verifiable regulatory compliance, robust factory documentation, and data transparency that can survive stringent customs audits, tender checks, and vendor qualification reviews. In this [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/why-fda-510k-clearance-and-eu-ce-mdr-certification-should-anchor-your-hearing-aid-sourcing-strategy/">Why FDA 510(k) Clearance and EU CE MDR Certification Should Anchor Your Hearing Aid Sourcing Strategy</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Gilead Sciences Inaugurates Advanced Research Centre in California</title>
		<link>https://www.worldpharmatoday.com/news/gilead-sciences-inaugurates-advanced-research-centre-in-california/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 10 Sep 2026 06:57:18 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/gilead-sciences-inaugurates-advanced-research-centre-in-california/</guid>

					<description><![CDATA[<p>Gilead Sciences has expanded its R&#038;D infrastructure with a new 182,000-square-foot facility in Foster City dedicated to inflammation, oncology, and data science.</p>
The post <a href="https://www.worldpharmatoday.com/news/gilead-sciences-inaugurates-advanced-research-centre-in-california/">Gilead Sciences Inaugurates Advanced Research Centre in California</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Research Peptide Quality: What Laboratories Need to Know</title>
		<link>https://www.worldpharmatoday.com/news/research-peptide-quality-what-laboratories-need-to-know/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 08 Sep 2026 10:12:16 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/titleresearch-peptide-quality-what-laboratories-need-to-know/</guid>

					<description><![CDATA[<p>Research Peptides in Modern Drug Discovery: Quality, Purity, and Sourcing Standards Peptides have been a part of research for many years. The way scientists handle peptides has changed a lot. New methods for making them, better tools to analyze them, machines that can screen them quickly, and new ways to change their structure have made [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/research-peptide-quality-what-laboratories-need-to-know/">Research Peptide Quality: What Laboratories Need to Know</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Biomarkers, Second Opinion, and Immunotherapy Planning for Stage 4 Colon Cancer With Booking Health</title>
		<link>https://www.worldpharmatoday.com/news/biomarkers-second-opinion-and-immunotherapy-planning-for-stage-4-colon-cancer-with-booking-health/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 04 Sep 2026 07:37:50 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/biomarkers-second-opinion-and-immunotherapy-planning-for-stage-4-colon-cancer-with-booking-health/</guid>

					<description><![CDATA[<p>In recent years, biomarkers have become an essential part of patient evaluation and are driving the overall therapeutic strategy. Accurate molecular profiling of the tumor before any intervention is an essential component of effective treatment planning for stage 4 colon cancer. Once we identify specific genetic changes, oncologists can tailor treatments to achieve the highest [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/biomarkers-second-opinion-and-immunotherapy-planning-for-stage-4-colon-cancer-with-booking-health/">Biomarkers, Second Opinion, and Immunotherapy Planning for Stage 4 Colon Cancer With Booking Health</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Purity on Paper Isn&#8217;t Enough: How Procurement Teams Are Raising the Bar on Synthetic Peptide Sourcing</title>
		<link>https://www.worldpharmatoday.com/news/purity-on-paper-isnt-enough-how-procurement-teams-are-raising-the-bar-on-synthetic-peptide-sourcing/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 04 Sep 2026 06:48:19 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/purity-on-paper-isnt-enough-how-procurement-teams-are-raising-the-bar-on-synthetic-peptide-sourcing/</guid>

					<description><![CDATA[<p>The quote said 98.5%. The certificate that arrived nine days later said 96.1%, and it covered a batch that had already gone into a dose-response series. We repeated the work. The reagent cost was trivial; the three weeks were not, and the conversation with a programme lead who had built a timeline around that data [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/purity-on-paper-isnt-enough-how-procurement-teams-are-raising-the-bar-on-synthetic-peptide-sourcing/">Purity on Paper Isn’t Enough: How Procurement Teams Are Raising the Bar on Synthetic Peptide Sourcing</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
